Iqvia Holdings Inc (NYSE:IQV) – Investment analysts at William Blair reduced their Q1 2018 earnings per share (EPS) estimates for shares of Iqvia in a report released on Thursday. William Blair analyst J. Kreger now forecasts that the medical research company will post earnings of $0.69 per share for the quarter, down from their prior forecast of $1.24. William Blair also issued estimates for Iqvia’s Q2 2018 earnings at $0.71 EPS, Q3 2018 earnings at $0.79 EPS, Q4 2018 earnings at $0.94 EPS, FY2018 earnings at $3.13 EPS, FY2019 earnings at $3.85 EPS and FY2020 earnings at $4.77 EPS.
Several other analysts also recently commented on the stock. Royal Bank of Canada set a $118.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a research report on Thursday. Piper Jaffray Companies reaffirmed a “hold” rating and set a $103.00 price objective on shares of Iqvia in a research report on Thursday. JPMorgan Chase & Co. raised their price objective on shares of Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday. Mizuho set a $97.00 price objective on shares of Iqvia and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $110.00 price objective on shares of Iqvia in a research report on Monday, January 22nd. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $110.02.
Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.34 by ($0.02). The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the business earned $1.09 EPS.
In related news, Director John Connaughton sold 1,163,191 shares of Iqvia stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of Iqvia stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total transaction of $764,776,314.00. The disclosure for this sale can be found here. In the last three months, insiders sold 8,727,078 shares of company stock valued at $890,124,079. 6.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. Winslow Evans & Crocker Inc. purchased a new position in Iqvia during the 4th quarter worth $123,000. Focused Wealth Management Inc purchased a new position in Iqvia during the 4th quarter worth $166,000. Valeo Financial Advisors LLC purchased a new position in Iqvia during the 4th quarter worth $170,000. IFP Advisors Inc purchased a new position in Iqvia during the 4th quarter worth $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Iqvia during the 4th quarter worth $209,000. 95.91% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/19/william-blair-analysts-reduce-earnings-estimates-for-iqvia-holdings-inc-iqv.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.